Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 1.00 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30055286 | 1.00 | IDO1 (1.00) | IDO1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL21496273 | 1.00 | IDO1 (1.00) | IDO1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL21496274 | 1.00 | IDO1 (1.00) | IDO1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL24118294 | 0.93 | IDO1 (0.86) | IDO1 | |
| SCHEMBL30056153 | 0.93 | IDO1 (0.86) | IDO1 | |
| SCHEMBL21496396 | 0.92 | IDO1 (0.85) | IDO1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL21496398 | 0.92 | IDO1 (0.85) | IDO1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL24117927 | 0.91 | IDO1 (0.83) | IDO1SMN1; SMN2 | |
| SCHEMBL24118298 | 0.91 | IDO1 (0.83) | IDO1SMN1; SMN2 | |
| SCHEMBL21496471 | 0.91 | IDO1 (0.83) | IDO1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478461-B2 | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478461-B2 | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | IDO1 1/4885KCNQ3 4162/4885KCNQ2 3812/4885 |
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885KCNQ3 4341/4885KCNQ2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.